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Abstract 
Activation of the immune system and increased synthesis of extracellular matrix 
proteins by fibroblasts are hallmarks in the pathogenesis of systemic sclerosis (SSc). The 
molecular mechanisms underlying the infiltration of inflammatory cells into the skin and the 
subsequent activation of fibroblasts are still largely unknown. Chemokines are a family of 
small molecules that are classified according to the position of NH2-terminal cysteine motif. 
Recent data indicate that chemokines and in particular two members of the subfamily of 
monocyte chemoattractant proteins, MCP-1 (CCL-2) and MCP-3 (CCL-7) might be involved 
in the pathogenesis of SSc. MCP-1 and MCP-3 are overexpressed by SSc fibroblasts and in 
skin lesions from SSc patients compared to healthy controls. MCP-1 and MCP-3 are 
chemotactic for inflammatory cells and stimulate their migration into the skin. In addition to 
their pro-inflammatory effects, MCP-1 and MCP-3 contribute to tissue fibrosis by activating 
the synthesis of extracellular matrix proteins in SSc fibroblasts. Therapeutic strategies 
targeting MCP-1 have revealed promising results in several animal models of SSc. 
Antagonists against the receptor CCR2 are currently tested in clinical trials of a variety of 
diseases and represent also interesting candidates for target-directed therapy in SSc. 
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Introduction 
Systemic sclerosis (SSc) is a generalized fibrotic disease of unknown etiology, which 
affects the skin and various internal organs. Histopathological hallmarks of SSc are 
inflammatory infiltrates in early disease stages and an accumulation of extracellular matrix 
proteins leading to tissue fibrosis. Inflammatory infiltrates are dominated by macrophages and 
T cells and are localized preferentially in perivascular areas. Inflammatory cells migrate into 
the skin before a significant accumulation of extracellular matrix can be observed. Tissue 
fibrosis in SSc is caused by an overproduction of extracellular matrix components by 
activated fibroblasts [1]. SSc fibroblasts produce increased amounts of extracellular matrix 
proteins, which accumulate in the skin [2]. Although significant progress has been made in 
analyzing the different components of the extracellular matrix, the mechanisms for the 
pathologic activation of fibroblasts in SSc have only partially been identified. Most authors 
favour an interaction of different cells types orchestrated by pro-inflammatory and pro-
fibrotic cytokines. This concept is supported by the observation that fibroblast, which produce 
the highest amount of extracellular matrix proteins are often localized in close proximity to 
the inflammatory infiltrates [1]. According to this hypothesis, pro-inflammatory cytokines 
such as MCP-1 are released in early disease stages of SSc. The pro-inflammatory cytokines 
attract T cells and mononuclear cells to the skin, which in turn release pro-fibrotic cytokines 
such as transforming growth factor  (TGF) and interleukin 4 (IL-4) [1]. These pro-fibrotic 
cytokines then activate in turn the synthesis of extracellular matrix in dermal fibroblasts 
leading to tissue fibrosis in later stages of the disease. However, the mechanisms that 
stimulate the initial release of pro-inflammatory cytokines, which then trigger the migration 
and activation of inflammatory cells in the early pathogenesis of SSc, remain elusive. 
 
Structure and classification of chemokines  
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Chemokines are a family of small molecules with a molecular weight of 8 to 14 kilo 
Dalton. To date, approximately 50 human chemokines and 20 G-protein-coupled chemokine 
receptors have been identified (Supplementary Tables 1-3). Based on their genetic 
organization and the position of two highly conserved cysteine residues at the N-terminus, 
chemokines can be divided into four subgroups, the CC-, CXC-, C- and CX3C-family [3]. In 
the CXC chemokine family, the two N-terminal cysteine residues are separated by a variable 
amino acid. Genes from this family are clustered at human chromosome 14q12-21. Based on 
the presence or absence of a glutamic acid - leucine - arginine motif at the N-terminus, CXC 
chemokines can be subclassified into ELR+ and ELR- molecules. Chemokines of the CC 
family have adjacent cysteines close to the N-terminus, and their genes cluster - with some 
exceptions - at 17q11.2-12 [4]. As a general rule, members of the CC family are primarily 
targeting monocytes and T cells, whereas CXC chemokines affect mainly neutrophils. The 
two members of the C chemokine family, lymphotactin α and lymphotactin β are 
characterized by a single cysteine residue at the N-terminus. The only member of the CX3C 
chemokine family, fractalkine, has a typical chemokine domain at its N-terminus except for 
the presence of three amino acids between the first two cysteines. Fractalkine is the only 
chemokine that is membrane-bound [5]. Beside the chemokine domain, fractalkine consists of 
a mucin-like stalk, a transmembrane domain, which anchors it to the plasma membrane and a 
cytoplasmic domain. An alternative classification system distinguishes inducible chemokines 
with pro-inflammatory properties from homeostatic cytokines, which are constitutively 
expressed [6].  
 
Chemokine receptors 
Chemokine receptors are 7-transmembrane-domain receptors, which are coupled to 
heterotrimeric G-proteins [7]. To induce migration of target cells along a chemotactic 
gradient, the release of the β subunits from the heterotrimeric G-protein is required. Among 
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other pathways, the β subunits activate then directly phosphoinositide-specific phospholipase 
C (PLC) isoenzymes leading to the formation of inositol-1,4,5-trisphosphate and a rise of the 
intracellular calcium concentration. The signals mediated by chemokine receptors (except 
CXCR 4) are short and transient. The rapid termination of receptor activity is achieved by 
phosphorylation at multiple sites of the cytoplasmic C-terminus, homologous and 
heterologous desensitization and subsequent internalization [7]. It is noteworthy that the 
chemokine/chemokine receptor system is highly redundant in that most chemokine receptors 
bind several different chemokines and most chemokines bind to several different receptors 
(Supplementary Tables 1, 2 and 3).  
 
Function of chemokines  
During inflammation, sentinel cells at the inflammatory focus release chemokines and 
generate a chemotactic gradient to surrounding blood vessels. Presentation of chemokines on 
endothelial cells induces rolling and transendothelial migration of leukocytes. For the 
migration along the chemotactic gradient sensing of subtle differences in the concentration of 
chemokines is required. This occurs via the accumulation of intracellular signalling molecules 
at the leading edge of migrating cells, whereas the chemokine receptors themselves remain 
uniformly distributed over the plasma membrane during migration [3,8]. The mechanisms, 
how the chemotactic gradient is leading to the asymmetric distribution of intracellular 
signalling molecules remains to be elucidated.  
Although leukocyte chemotaxis and lymphocyte development are the most prominent 
features of chemokines, chemokines also possess other biologic activities [3]. Of particular 
interest for SSc, chemokines are also involved in the regulation of angiogenesis and 
vasculogenesis. A structural domain of the CXC chemokine family determines their 
angiogenic potential [9,10]. The N-terminus of CXC family members such as IL-8 (CXCL8) 
and growth-related oncogenes (GRO) α, β, and γ (CXCL1-3), contain three amino acid 
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residues (Glu-Leu-Arg), the so-called ELR motif. These ELR(+) CXC chemokines have 
strong chemotactic effects on endothelial cells and can induce neovascularization in vivo, 
even in the absence of leukocytes. In contrast, ELR(-) CXC chemokines such as platelet 
factor 4 (CXCL4) and monokine-induced by IFN- (MIG, CXCL9) are potent inhibitors of 
angiogenesis. Other functions of chemokines include control of cell proliferation, alteration of 
the expression of adhesion molecules and regulation of interactions between HIV and target 
cells [10]. 
 
Expression of MCP-1 in the skin of SSc patients 
Five members of the family of monocyte chemoattractant proteins have been 
identified so far. MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (CCL7), MCP-4 (CCL13) and 
MCP-5 (CCL12) constitute a subfamily within the CC chemokines [11,12]. The amino acid 
sequences among the monocyte chemoattractant proteins are highly conserved with up to 70% 
homology. They belong to the functional class of inducible, pro-inflammatory chemokines 
and have been shown to be chemotactic for monocytes, eosinophils and basophils [11]. Two 
members of the family of monocyte chemoattractant proteins, MCP-1 and MCP-3 have been 
linked to the pathogenesis of SSc. 
MCP-1 (CCL2) is a 99 amino acid protein that has been shown to be identical to the 
murine JE gene product [13]. MCP-1 can be released by a large variety of cells including 
fibroblasts, epithelial cells, mononuclear cells, endothelial cells and smooth muscle cells [14-
16]. In SSc, numerous groups have shown that MCP-1 is expressed abundantly in the skin of 
patients on the mRNA and protein level [17-20]. In skin biopsies from involved skin areas, 
MCP-1 expression was detected by in-situ hybridization and immunohistochemistry in 
mononuclear cells, fibroblasts, endothelial cells and keratinocytes. Interestingly, a similar 
expression pattern for MCP-1 was also found at non-fibrotic skin sites, suggesting that MCP-
1 might play a role in the initiation of tissue fibrosis [17]. In early, inflammatory stages, 
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MCP-1 was expressed mainly by infiltrating mononuclear cells, whereas in later, fibrotic 
disease stages, fibroblasts became the major source for MCP-1 in the dermis of SSc patients. 
In contrast, the expression of MCP-1 mRNA in the skin of healthy individuals was limited to 
a few scattered epidermal and dermal cells and no expression of MCP-1 protein was 
detectable on the protein levels by immunohistochemistry. 
In contrast to the situation in vivo, a constitutive expression of MCP-1 mRNA and 
protein was detected in cultured fibroblasts not only from SSc fibroblasts, but also from 
healthy controls [17]. The expression of MCP-1 was not only found in the presence of fetal 
calf serum, but also after growth factor deprivation. The levels of platelet derived growth 
factor (PDGF) are elevated in SSc patients and are thought to contribute to the pathogenesis 
of SSc. We could demonstrate that PDGF induces dose-dependently the expression of MCP-1 
in cultured dermal fibroblasts. Concentrations up to 10 ng/ml PDGF significantly induced 
MCP-1 mRNA compared to unstimulated fibroblast cultures. In contrast to the data obtained 
for MCP-1 protein, no further increase of MCP-1 mRNA was observed with higher 
concentrations of PDGF. These data indicate that at higher concentrations of PDGF, the 
induction of MCP-1 might be driven by increased translation, in addition to increased 
transcription [17]. 
Karrer et al. analyzed in an initial study on a limited number of German SSc patients 
that the frequency of the -2518 G single nucleotide polymorphism of the MCP-1 gene [21]. 
They found that the GG genotype was more frequent in their collective of SSc patients than in 
healthy volunteers. Of particular interest, the expression of MCP-1 was higher in GG 
homozygous patients than in patients with the AG or the AA genotype. However, no 
significant differences in the prevalence of this polymorphism were found in two larger 
follow-up studies from the UK and from the Czech Republic [22,23].  
 
MCP-1 in fibrotic diseases 
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In addition to increased expression in the skin, MCP-1 levels are also increased in the 
blood of SSc patients [19,24-27]. Serum levels of MCP-1 might be particularly high in 
patients with early and diffuse disease [25,26]. However, another report did not find changes 
in the serum concentrations of MCP-1 over time [24]. High serum levels of MCP-1 might also 
identify SSc patients with increased risk of major organ involvement. Three groups reported 
independently that serum levels of MCP-1 were higher in patients with pulmonary fibrosis 
[19,25,27]. In addition, correlations with renal and cardiac involvement have been described 
[25,27]  
MCP-1 is expressed in SSc from very early stages on and it is a potent chemoattractant 
for mononuclear cells [28]. Local expression of MCP-1 in the skin of SSc patients might 
establish a chemotactic gradient guiding inflammatory cells into the skin of SSc patients. 
Indeed, experiments with blocking antibodies against MCP-1 revealed that cultured 
fibroblasts from SSc patients promote migration of mononuclear leukocytes by the release of 
biologically active MCP-1 [17,29]. MCP-1 might therefore play a key role in the infiltration 
of the skin by mononuclear cells and the development of inflammatory infiltrates in early 
stages of SSc, which might stimulate in turn the activation of resident fibroblasts.  
Indeed, inhibition of MCP-1 exerts potent anti-fibrotic effects in several inflammation 
driven models of tissue fibrosis. In a murine model of crescentic nephritis, a strong induction 
of MCP-1 was observed that was accompanied by an influx of inflammatory cells and the 
development of fibrosis [30]. Blocking MCP-1 by anti-MCP-1 antibodies resulted in a 
reduced tissue infiltration by inflammatory cells and a decreased deposition of type I collagen 
in the kidney [31]. MCP-1 has also been suggested to play a role in experimental pulmonary 
fibrosis. In bleomycin-induced lung fibrosis, MCP-1 is expressed in a time-dependent manner 
after exposure to bleomycin with highest levels of MCP-1 observed in areas of active fibrosis 
[32]. MCP-1 also plays a key role in the pathogenesis of bleomycin-induced dermal fibrosis, a 
common model of SSc. Mice lacking MCP-1 are protected from bleomycin-induced dermal 
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fibrosis [33]. The number of inflammatory cells and the accumulation of collagen in lesional 
skin of mice lacking MCP-1 upon bleomycin challenge were strongly reduced compared to 
wild-type mice. Furthermore, treatment with SKL-2841, a small molecule antagonist of MCP-
1 and MIP-1β prevented bleomycin-induced dermal fibrosis [34].  
The important role of MCP-1 in pulmonary fibrosis was supported by studies on mice 
lacking CCR2, the receptor for MCP-1. After intratracheal instillation of bleomycin or 
fluorescein isothiocyanate, the hydroxyproline content of the lungs was significantly reduced 
in CCR2 knockout animals compared to wild-type mice and CCR2 knockout mice were 
protected from fibrosis [35,36].  
Activation of CCR2 signalling by MCP-1 and MCP-5 might also play an important 
role for the migration of fibrocytes into affected tissues in fibrotic diseases. Fibrocytes are 
bone marrow derived, circulating fibroblast like cells that can be identified by their expression 
of the haematopoietic stem cell antigen CD34, the common leukocyte antigen CD45 and type 
I collagen. In culture, these cells can acquire a myofibroblast phenotype and produce large 
amounts of collagen. Fibrocytes have been implicated in the pathogenesis of fibrotic disease 
in particular in pulmonary fibrosis [37]. Murine fibrocytes isolated from fibrotic lungs 
expressed CCR2 and migrated towards the CCR2 ligands MCP-1 and MCP-5 in vitro [38]. In 
mice lacking CCR2, fibrocyte recruitment was reduced upon challenge with intrapulmonary 
FITC. Recruitment of fibrocytes in CCR2 knockout mice was restored, when CCR2 knockout 
mice were transplanted with bone marrow from wildtype mice [38]. These findings 
demonstrate an important role for CCR2 for the recruitment of fibrocytes in mice. However, 
CCR2 signalling might be less important in humans. First, human fibrocytes express lower 
levels of CCR2 than murine fibrocytes [39]. Second, no human homolog of the CCR2 agonist 
MCP-5 has been identified so far and MCP-5 might only be relevant to murine biology.  
 
Direct effects of MCP-1 on fibroblasts 
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Whether MCP-1 is directly involved in the activation of dermal fibroblasts leading to 
the accumulation of extracellular matrix proteins in SSc is controversial. We did not observe 
any effects of recombinant MCP-1 on the synthesis of type I collagen in our fibroblast 
cultures as assessed by real-time PCR, radioimmunoassay for the N-terminal propeptide of 
type I collagen and direct measurements of the collagen concentrations with the SirCol 
collagen assay [17,40]. In addition, blocking antibodies to MCP-1 did not reduce the basal 
collagen synthesis of cultured fibroblasts from SSc patients and healthy controls [40]. Our 
observations were confirmed by Galindo and coworkers, who also did not observe stimulatory 
effects of MCP-1 on cultured dermal fibroblasts [18]. Consistently, the receptor for MCP-1, 
CCR2, was not detectable in our fibroblasts by real-time PCR, in-situ hybridization and 
FACS [40]. In contrast, Yamamoto et al detected a significant increase of α1(I) collagen 
mRNA after incubation of cultured dermal fibroblasts with recombinant MCP-1 by Northern 
blot hybridization [41]. A possible explanation for these distinct findings might be different 
cell sources, since Yamamoto et al used outgrowth cultures, whereas fibroblasts were 
obtained from biopsies by enzymatic digestion in the other studies. Alternatively, fibroblasts 
might express CCR2 only during a short time-frame in the course of the disease and then lose 
the expression of receptors for MCP-1. Along this line, Carulli et al. detected signals for 
CCR2 by flow cytometry only in a subset of fibroblast cultures established from patients with 
early SSc [42]. Consistently, expression of CCR2 was detected only in patients with early, 
diffuse disease by immunohistochemistry. Double labeling experiments demonstrated that 
CCR2 positive fibroblasts expressed α-smooth muscle actin, suggesting that the expression of 
CCR2 might be restricted to myofibroblasts [42]. Of interest, CCR2 positive fibroblasts also 
overexpressed MCP-1, suggesting a possible autocrine activation loop in myofibroblasts. 
Indeed, inhibition of MCP-1 or CCR2 attenuated the expression of α-smooth muscle actin. 
Thus, MCP-1 might stimulate the differentiation of a subset of resting fibroblasts into 
metabolically active myofibroblasts in an autocrine manner in early stages of SSc.  
 10  
In addition to potential effects on collagen production, MCP-1 might also alter matrix 
turn-over by regulating the expression of matrix-degrading enzymes and their inhibitors. 
Yamamoto and coworkers demonstrated that MCP-1 upregulates the expression of tissue 
inhibitor of matrix metalloproteinase-1 (TIMP-1) in dermal fibroblasts on the mRNA and on 
the protein level [43]. Of note, the expression of MMP-1 and MMP-2 was also increased. The 
induction of MMP-1 might partially be mediated by IL-1. MCP-1 stimulated the expression of 
interleukin-1 in parallel to MMP-1 and pre-incubation with IL-1 receptor antagonist reduced 
the stimulatory effects of MCP-1 on MMP-1 [43].  
 
Alternative receptors for MCP-1 in SSc 
 Since only a subset of fibroblasts might express CCR2 for a short time period, the 
expression of alternative receptors for MCP-1 in SSc patients was analyzed. Beside CCR2, 
three other receptors have been shown to bind MCP-1, namely D6, the Duffy antigen receptor 
for chemokines (DARC) and US28. In contrast to CCR2, all of these receptors are not 
specific for MCP-1, but bind several other cytokines with similar affinity. D6 is a seven-
transmembrane spanning receptor that is most closely related to CCR4 and IL-8R [44]. 
DARC has first been identified as the Duffy antigen on red blood cells. However, DARC is 
not only expressed by erythrocytes, but also by numerous other cell types including 
fibroblasts. Furthermore, the expression of DARC is not limited to Duffy antigen positive 
individuals, but also DARC can be found in individuals, whose erythrocytes do not express 
the Duffy antigen [45]. To date, no signalling has been observed upon binding of ligands to 
these receptors and D6 and DARC have been suggested to function of decoy receptors 
[45,46]. Consistent with this hypothesis, mice lacking D6 exhibit severe hyperinflammatory 
responses. In contrast to D6 and DARC, US28 protein is a functional chemokine receptor 
[47,48]. US28 protein is encoded by the open reading frame 28 of the cytomegalovirus 
[47,48] and has been shown to accelerate inflammation in the presence of MCP-1 [49]. D6 
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and US28 were not expressed in the skin of SSc patients or controls. mRNA for DARC was 
detectable in SSc fibroblasts in vitro and in vivo. However, the expression levels were low 
and no differences were observed between SSc patients and healthy individuals [40]. 
Together with the fact that no signalling has been detected upon chemokine binding to 
DARC, these data suggest that DARC does not contribute to the activation of pro-fibrotic 
signalling cascades by MCP-1 in SSc fibroblasts. In summary, we did not detect any 
functional receptor for MCP-1 on fibroblasts and direct stimulation of fibroblasts with MCP-1 
did not induce the synthesis of collagen.  
 
Indirect, T cell dependent induction of collagen by MCP-1 
MCP-1 has consistently been shown to be overexpressed in SSc. Furthermore, animal 
models of different fibrotic diseases implicate a pro-fibrotic role of MCP-1, but direct 
stimulatory effects of MCP-1 on the collagen production by SSc fibroblasts have been 
observed only in a subset of fibroblast cultures. Thus, the pro-fibrotic effects of MCP-1 may 
require interactions with other cell types such as T cells. In skin specimens of patients with 
SSc, Mavalia et al. found a predominance of Th2 cells, and there is increasing evidence that 
Th2 cytokines contribute to the deposition of collagen in fibrotic diseases such as SSc [50]. 
Among the Th2 cytokines, IL-4 is thought to play an important role in the pathogenesis of 
SSc. The levels of IL-4 are increased in the serum of SSc patients [51] and IL-4 is also 
overexpressed in the skin of SSc patients [52]. Furthermore, IL-4 has been shown to stimulate 
directly and potently the synthesis of extracellular matrix proteins in dermal fibroblasts 
[40,53]. The importance of IL-4 for the development of fibrosis in vivo is emphasized by the 
observation that treatment with neutralizing anti-IL-4 antibodies prevents the deposition of 
collagen in the tight-skin-1 mouse model of SSc and leads to normalization of the dermal 
collagen content [54]. 
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Consistent with the theory of an indirect role of MCP-1 in fibrotic processes, we 
recently demonstrated that MCP-1 can induce a Th2 differentiation in Th0 cells resulting in 
an increased release of IL-4 (Figure 1) [40]. When Th0 cells were stimulated for 7 days by IL-
2 and anti-CD3/CD28, the level of IL-4 released by these T cells was significantly higher in 
the presence of MCP-1. The level of MCP-1 increased further, when the cells were re-
stimulated with MCP-1 and anti-CD3/CD28 after a resting period of 4 days. We could also 
show that glycosaminoglycans function as a local reservoir for MCP-1 in the skin of SSc 
patients [40]. Like other components of the extracellular matrix, glycosaminoglycans are 
greatly enriched in the skin of patients with SSc compared to healthy controls. The positively 
charged C-terminus of MCP-1 can bind to negatively charged glycosaminoglycans via ionic 
interactions [55,56]. We could demonstrate that MCP-1, which is re-released from 
glycosaminoglycans in a time-dependent manner, is capable of stimulating efficiently the 
production of IL-4 in Th0 cells [40].  
Thus, direct and indirect effects might contribute to the pro-fibrotic effects of MCP-1 
in SSc. MCP-1 might directly stimulate the collagen production in a subset of patients in early 
stages of the disease.  In other patients or in other stages of the disease, the pro-fibrotic effects 
of MCP-1 might preferentially indirectly by stimulating the release of IL-4 from T cells. 
 
MCP-3 in the pathogenesis of SSc 
MCP-3 (CCL7) is an 11 kilo Dalton protein that is closely related to MCP-1. The 
chemotactic potency of MCP-3 for monocytic cells is similar to that of MCP-1. However, the 
chemotactic effects of MCP-3 are broader than that of MCP-1. Since MCP-3 binds not only to 
CCR2, but also with high affinities to CCR1 and CCR3 [11], MCP-3 is also chemotactic for 
dendritic cells and granulocytes in addition to monocytes, NK cells and lymphocytes [11,57]. 
The expression patterns of MCP-3 are similar to MCP-1, but MCP-3 is released in lower 
levels by dermal fibroblasts than MCP-1 [58].  
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Tight skin mice-1 (Tsk-1) are widely used as an animal model of SSc. Ong and co-
workers recently demonstrated that MCP-3 mRNA and protein are highly upregulated in 
cultured fibroblasts of neonatal tight skin mice [59]. Immunohistochemistry demonstrated an 
abundant expression of MCP-3 in the dermis of Tsk-1 mice. In contrast, the expression of 
MCP-3 was limited to perifollicular cells in control mice. In SSc patients, MCP-3 was 
expressed by mononuclear cells, dermal fibroblasts and basal keratinocytes of all patients. In 
healthy individuals, MCP-3 was detected only in basal keratinocytes. The release of MCP-3 
was stimulated by TGFβ in murine fibroblasts [59]. The induction of MCP-3 by TGFβ 
depended partially on p42/44 ERK activation, since inhibitors of p42/44 ERK prevented the 
upregulation. MCP-3 might also play a role in the pathologic activation of skin fibroblasts in 
SSc. In reporter assays, the promoter of the murine pro α2 (I) collagen gene is activated by 
MCP-3 [59]. It has not been determined yet, whether MCP-3 can upregulate the collagen 
synthesis indirectly by inducing the release of pro-fibrotic mediators by T cells. It has not 
been determined yet, whether MCP-3 also might stimulate Th2 polarization of T cells. 
Although the importance of MCP-3 needs to be confirmed in animal models for tissue 
fibrosis, MCP-3 might play an important role in the accumulation of extracellular matrix in 
SSc.  
 
Implications for therapy 
During the last years, blocking of chemokine signalling has gained growing interest as 
a potential new therapeutic strategy. In general, the action of chemokines can be blocked by 
chemokine-specific neutralizing antibodies, chemokine receptor antagonists or the inhibition 
of intracellular signalling pathways, which are activated by binding of chemokines to their 
receptors [60]. The proof of concept that antagonizing of chemokines is a valid therapeutic 
approach has been shown in animal models for a variety of diseases. For example, 
administration of an N-terminal truncated MCP-1 analogue that exerts antagonistic effects on 
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CCR2 prevents the onset of arthritis in the MRL-lpr mouse model of rheumatoid arthritis 
[61]. Furthermore, BX 471, a potent and specific CCR1 antagonist has been developed, which 
can be administered orally [62]. A new class of small molecule CCR2 antagonists was 
recently evaluated  [63,64]. These small molecule CCR2 antagonists are potent inhibitors of 
monocyte responses to MCP-1, they are specific for CCR2 and have appropriate 
pharmacokinetics for oral applications in vivo. The efficiency of these antagonists was 
investigated in several inflammatory conditions in vivo. In a mouse model for delayed type 
hypersensitivity, the rodent-active CCR2 antagonist INCB3344 suppressed the influx of 
macrophages and other inflammatory cells. Similar results were obtained with the related 
inhibitor INCB3268 in primates [64]. These inhibitors also blocked dose-dependently the 
influx of macrophages into the peritoneal cavity after thioglycolate challenge [63]. 
Furthermore, treatment with INCB3344, has been shown to reduce efficiently clinical signs of 
adjuvant arthritis, when initiated at the onset of arthritis. Histological analysis demonstrated 
not only a marked suppression of inflammation, but also a significant reduction of bone 
resorption [63]. The authors claimed that CCR2 antagonists might selectively inhibit the 
inflammatory phases, but not affecting immune activation and that CCR2 inhibitors might 
therefore represent a novel class of anti-inflammatory drugs without severe 
immunosuppressive side-effects. Because of the encouraging animal data, this group of small 
molecule CCR2 inhibitors is currently evaluated in clinical trials [63].  
Harrington and colleagues chose a different approach to target MCP-1 signalling. Instead of 
using a small molecule inhibitor of CCR2, they used monoclonal human anti-MCP-1 
antibodies (ABN912) and evaluated their efficacy for the treatment of rheumatoid arthritis in 
a placebo-controlled dose escalation trial [65]. ABN912 was well tolerated with no 
differences in the incidence of adverse events between placebo and treatment groups. 
However, after an initial drop, the total serum levels of MCP-1 unexpectedly increased dose-
dependently up to 2000 fold in patients treated with ABN912 and remained elevated 
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throughout the observation period of 180 days [65]. These effects might be explained by rapid 
binding of intravascular MCP-1 by ABN912 and subsequent mobilization of MCP-1 from 
extravascular compartments, e.g. from glycosaminoglycans. Consistent with the increase in 
circulating MCP-1, no clinical improvement was seen in patients treated with ABN912. 
Instead, the serum levels of C-reactive protein (CRP) and the number of sublining 
macrophages tended to increase in patients treated with ABN912. The results of this study do 
question the strategy of targeting MCP-1 with neutralizing antibodies, because subsequent 
increases in serum levels might be a general phenomenon for MCP-1 and all other 
chemokines that bind to glycosaminoglycans and are therefore stored in large quantities in the 
extracellular matrix. In general, strategies targeting CCR2 might be more potent than 
inhibition of MCP-1 for two reasons: (i) inhibitors of CCR2 should not lead to a mobilization 
of MCP-1 from extravascular stores, (ii) CCR2 is also a receptor for MCP-3 and inhibition of 
CCR2 thus targets simultaneously two pro-fibrotic cytokines, MCP-1 and MCP-3. CCR2 
antagonists are currently developed by a number of different pharmaceutical companies and 
are tested in clinical trials for various diseases. Table 1 summarizes the current status of 
clinical testing of these CCR2 antagonists. However, a recent trial with the human CCR2 
blocking antibody MLN1202 in patients with rheumatoid arthritis failed to show 
improvement [66]. Treatment with MLN1202 reduced the levels of free CCR2 on synovial 
monocytes, but did not alter the expression of synovial biomarkers or the clinical course. This 
controlled phase IIa trial was underpowered with only seven to nine patients per group and 
was thus not designed to detect clinical outcome. Furthermore, the observation time was 
limited to 6 weeks. Prolonged treatment might be need before beneficial effects can be 
detected. Finally, the authors also focussed on markers of monocyte activation and did not 
analyze fibroblasts and T cells, which are thought to mediate the pro-fibrotic effects of MCPs 
in SSc. Thus, the results of this trial do not exclude in effacacy of CCR2 antagonists in SSc.  
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Summary  
MCP-1 and MCP-3 have been characterized as important players in the pathogenesis 
of systemic sclerosis that might control inflammation of fibrosis. MCP-1 is overexpressed in 
the skin of SSc patients and is able to initiate the migration of inflammatory cells from the 
blood into involved tissues. MCP-1 plays also an important role in the development of skin 
fibrosis in SSc. MCP-1 induces a Th2 differentiation in Th0 cells. Th2 cells release increased 
amounts of IL-4, which stimulates in turn the collagen synthesis in dermal fibroblasts. In 
addition, MCP-1 might stimulate directly the production of extracellular matrix proteins in a 
subset of SSc fibroblasts. MCP-3 is overexpressed as well in SSc and activates collagen 
production in dermal fibroblasts. Targeting of MCP-1 and MCP-3 might offer a great 
potential for novel therapeutic agents. Inhibitors of the MCP receptor CCR2 have been 
developed recently and are currently tested in clinical trials. 
 
  
 17  
  
Conflict of Interest 
The authors declare herein that they have no conflict of interest. 
 
 
Funding 
Grant support was provided from the grant A20 of the Interdisciplinary Center of Clinical 
Research (IZKF) in Erlangen and the Career Support Award of Medicine of the Ernst Jung 
Foundation (to JHWD) 
 
 
Key Messages 
 MCP-1 and MCP-3 are overexpressed by SSc fibroblasts and in skin lesions from SSc 
patients  
 MCP-1 and MCP-3 stimulate the synthesis of extracellular matrix proteins in SSc 
fibroblasts 
 Inhibition of MCP-1 signalling had promising anti-fibrotic effects in several animal 
models of SSc and antagonists against the receptor CCR2, which are currently tested in 
clinical trials of a variety of disease, might represent interesting candidates for target-
directed therapy in SSc 
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Table 
 
Company Name of CCR2 
antagonist 
Type of trial Reference 
Incyte Corporation 
 
Pfizer  
INCB 8696 
 
PF-4136309 
Phase I, planed for multiple 
sclerosis 
Phase II pain in knee 
osteoarthritis  
http://www.incyte.com 
 
http://www.clinicaltrials.
gov 
ChemoCentryx, Inc CCX140 Phase I  http://www.chemocentry
x.com 
Bristol-Myers 
Squibb 
BMS-741672 Proof of Confidence in 
Insulin Resistance 
Phase II for neuropathic 
pain 
http://www.clinicaltrials.
gov 
http://ctr.bms.com/ 
Millennium 
Pharmaceuticals 
MLN1202 Phase II of patients at high 
risk for atherosclerosis 
completed 
RCT with rheumatoid 
arthritis completed 
http://www.mlnm.com 
 
 
Arthritis Rheum. 2008 
Jun 24;58(7):1931-1939. 
Table 1: Companies with CCR2 antagonists and current status of clinical development. This 
list is not exhaustive. RCT = randomized controlled trial 
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Figure legend 
Figure 1: Proposed function of MCP-1 (CCL2) in the pathogenesis of systemic sclerosis. 
Dermal fibroblasts act as sentinel cells and release MCP-1 in early stages of SSc. PDGF and 
IL-1 contribute to the induction of MCP-1 in dermal fibroblasts, resulting in a further 
increase of the expression of MCP-1. MCP-1 attracts mononuclear cells across the endothelial 
cell barrier into the dermis. MCP-1 might stimulate directly the expression of collagen in a 
subset of SSc fibroblasts. MCP-1 contributes also indirectly to the accumulation of 
extracellular matrix in SSc. MCP-1 induces a Th2 differentiation in infiltrating Th0 cells. Th2 
cells release increased amounts of IL-4, which stimulates in turn the collagen synthesis in SSc 
fibroblasts. In this model, glycosaminoglycans function as a local reservoir for MCP-1. 
PDGF, platelet-derived growth factor; IL-1, interleukin-1; IL-4, interleukin-4. (Figure 
modified from [40]) 
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Supplementary text 
CC Chemokine / Receptor Family 
Systematic Name Human Ligand Chemokine Receptor(s) 
CCL1 
CCL2 
CCL3 
CCL4 
CCL5 
CCL6 
CCL7 
CCL8 
CCL9 / 10 
CCL11 
CCL12 
CCL13 
CCL14 
CCL15 
CCL16 
CCL17 
CCL18 
CCL19 
CCL20 
CCL21 
CCL22 
CCL23 
CCL24 
CCL25 
CCL26 
CCL27 
CCL28 
I-309 
MCP-1 / MCAF 
MIP-1α  
MIP-1β  
RANTES 
C10, MRP-2 
MCP-3 
MCP-2 
MRP-2, CCF18, MIP-1γ 
Eotaxin 
MCP-5 
MCP-4 
HCC-1 
HCC-2 / Lkn-1 / MIP-1δ 
HCC-4 / LEC 
TARC 
DC-CK1  
MIP-3β / ELC / exodus-3 
MIP-3α / LARC / exodus-1 
6Ckine / SLC / exodus-2 
MDC / STCP-1 
MPIF-1 
MPIF-2 / Eotaxin-2 
TECK 
Eotaxin-3 
CTACK / ILC / skinkine 
MEC 
CCR8 
CCR2 
CCR1, CCR5 
CCR5 
CCR1, CCR3, CCR5 
CCR1? 
CCR1, CCR2, CCR3 
CCR3 
CCR1 
CCR3 
CCR2 
CCR2, CCR3 
CCR1 
CCR1, CCR3 
CCR1 
CCR4 
Unknown 
CCR7 
CCR6 
CCR7 
CCR4 
CCR1 
CCR3 
CCR9 
CCR3 
CCR10 
CCR3, CCR10 
Supplementary Table 1: Proposed new nomenclature for CC chemokines (10). Only the 
main receptors for each chemokine are listed, although some chemokines bind to additional 
receptors.  
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CXC Chemokine / Receptor Family 
Systematic Name Human Ligand Chemokine Receptor(s) 
CXCL1 
CXCL2 
CXCL3 
CXCL4 
CXCL5 
CXCL6 
CXCL7 
CXCL8 
CXCL9 
CXCL10 
CXCL11 
CXCL12 
CXCL13 
CXCL14 
CXCL15 
CXCL16 
CXCL17 
GROα / MGSA-α 
GROβ / MGSA-β 
GROγ / MGSA-γ 
PF4 
ENA-78 
GCP-2 
NAP-2 
IL-8 
MIG 
IP-10 
I-TAC 
SDF-1α / β 
BLC / BCA-1 
BRAK / bolekine 
unknown (Mouse Ligand: lungkine) 
SRPSOX 
DMC, VCC-1 
CXCR2 > CXCR1 
CXCR2 
CXCR2 
Unknown 
CXCR2 
CXCR1, CXCR2 
CXCR2 
CXCR1, CXCR2 
CXCR3 
CXCR3 
CXCR3 
CXCR4 
CXCR5 
unknown 
unknown 
CXCR6 
unknown 
Supplementary Table 2: Proposed new nomenclature for CXC chemokines (10). Only the 
main receptors for each chemokine are listed, although some chemokines bind to additional 
receptors.  
 26  
 Chemokine Receptor Chemokine-Ligand 
CCR1 
CCR2 
CCR3 
CCR4 
CCR5 
CCR6 
CCR7 
CCR8 
CCR9 
CCR10 
HCC-1, HCC-2, HCC-4, MCP-3, MIP-1, MPIF-1, RANTES 
CCL12, MCP-1, MCP-3, MCP-4 
Eotaxin, Eotaxin-2, HCC-2, MCP-2, MCP-3, MCP-4, MEC, RANTES 
MDC, TARC  
MIP-1, MIP-1, RANTES 
MIP-3 
MIP-3, 6Ckine 
I-309 
TECK 
CTACK, MEC 
CXCR1 
CXCR2 
CXCR3 
CXCR4 
CXCR5 
CXCR6 
GCP-2, GRO, IL-8 
ENA78, GCP-2, GRO, GRO, GRO, IL-8, NAP-2 
IP-10, I-TAC, Mig 
SDF-1 
BCA-1 
CXCL16 
XCR1 Lymphotactin α, Lymphotactin β 
CX3CR1 Fractalkine 
Supplementary Table 3: Chemokine receptors. (For new nomenclature see Supplementary 
Tables 1 and 2)  
 
Abbreviations: 
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6Ckine, chemokine with 6 cysteines; BCA-1, B cell-activating chemokine-1; BLC, B 
lymphocyte chemoattractant; BRAK, breast and kidney; CCL-12, CC ligand 12; CTACK, 
cutaneous T cell-attracting chemokine; CXCL16, CXC ligand 16; DC-CK1, dentritic cell 
chemokine 1; ELC, Epstein Barr virus-induced receptor ligand chemokine; ENA-78, 
epithelial derived neutrophil attractant-78, GCP-2, granulocyte chemotactic protein-2; GRO, 
Growth-regulated oncogene; HCC, hemofiltrate CCCC chemokine; IL-8, interleukin-8; ILC, 
interleukin-11 receptor alpha-locus chemokine; I-TAC, interferon-inducible T cell -
chemoattractant; IP-10, interferon-inducible protein 10; LARC, liver- and activation-regulated 
chemokine; LEC, Liver-expressed chemokine; Lkn-1, leukotactin-1; MCAF, monocyte 
chemotactic and activating factor; MCP, monocyte chemoattractant protein; MDC, 
macrophage-derived chemokine; MEC, mucosae-associated epithelial chemokine; MGSA, 
Melanoma growth stimulating activity; MIG, monokine-induced by  interferon; MIP, 
macrophage inflammatory protein; MPIF, Myeloid progenitor inhibitory factor; NAP-2, 
neutrophil activating protein-2; PF4, platelet factor 4; RANTES, regulated on activation 
normal T cell expressed and secreted; SDF-1, stromal cell-derived growth factor 1; SLC, 
secondary lymphoid tissue chemokine; STCP-1, stimulated T cell chemotactic protein; 
TARC, thymus- and activation-regulated chemokine; TECK, thymus-expressed chemokine 
